Burns J W & Co. Inc. NY Purchases 175 Shares of Novo Nordisk A/S (NYSE:NVO)

Burns J W & Co. Inc. NY grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,605 shares of the company’s stock after purchasing an additional 175 shares during the period. Burns J W & Co. Inc. NY’s holdings in Novo Nordisk A/S were worth $482,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Natixis Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC increased its position in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $86,000. Zions Bancorporation N.A. boosted its stake in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.1 %

Novo Nordisk A/S stock traded down $1.83 during mid-day trading on Monday, reaching $84.43. The stock had a trading volume of 7,237,434 shares, compared to its average volume of 7,400,001. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15. The company has a 50-day moving average price of $100.35 and a two-hundred day moving average price of $119.04. The company has a market capitalization of $378.88 billion, a price-to-earnings ratio of 27.32, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.